Advertise on podcast: Pathology News

Following the recent collaboration between Source BioScience and Sectra, join us for this short Pathology News interview, where Sidney Ocanagil-Tunstall speaks with Klaudyna Johnston and Chris Scarisbrick about connecting pathology services and helping improve diagnostic turnaround times in the NHS. In the conversation, Chris explains how Sectra’s Image Exchange Portal is evolving beyond image sharing to support the transfer of cases and associated workflows between organisations. Klaudyna discusses how this connectivity could reduce administrative workload, minimise reliance on transporting glass slides and help hospitals access additional reporting capacity when they need it. Looking ahead, the interview explores how more connected pathology networks could support collaboration, access to specialist expertise and flexible responses to growing demand. The discussion also considers how external diagnostic partners can act as an extension of NHS laboratories, helping teams make better use of available capacity.

In this episode, Sidney Ocanagil-Tunstall speaks with Dr Pierre Moulin, Chief Scientific Officer at Deciphex, following the company's recent announcement of CipherX, a new pathology AI engine designed to move beyond traditional foundation models and address a much broader range of diagnostic and research questions. Building on Deciphex's official launch of CipherX, Pierre challenges the industry's ongoing race towards bigger models and higher benchmark scores, questioning whether these advances are translating into meaningful improvements for pathologists and pharmaceutical researchers. He introduces the technology behind CipherX, explaining how its semantic layer transforms complex AI outputs into recognisable histopathological features, making results more interpretable, auditable and adaptable across different applications. The conversation explores how CipherX is already powering Deciphex's clinical diagnostic service, Diagnexia, and pharmaceutical research business, Patholytix, supporting diagnostic quality assurance, biomarker discovery and companion diagnostic development. Looking ahead, Pierre discusses the potential to accelerate AI development for a wider range of pathology questions, including rare diseases and complex diagnostic challenges, and why the future of computational pathology may depend less on building bigger models and more on making AI genuinely useful in clinical practice. Read more about the announcement: https://www.pathologynews.com/deciphex-launches-cipherx-a-step-beyond-foundation-models-an-ai-engine-for-any-pathology-question/

In Part 2 of the Pathology News Podcast, recorded at ECP 2026 in Stockholm, Nick Best continues his conversation with Dr. Orly Ardon, Director of Digital Pathology Operations at Memorial Sloan Kettering Cancer Center, and Chet Kondragunta, CEO of IraMatrix, to explore the practical implementation of AI-powered quality control in digital pathology. Orly shares how automated QC has transformed operations at Memorial Sloan Kettering, enabling the team to move from manually reviewing just 10–20% of scanned slides to quality checking every image without increasing staffing levels. Together, they discuss how automation can improve technician workflows, identify scanner and image quality issues, reduce storage costs and support more efficient, scalable digital pathology operations. Research Papers Discussed: Digital Slide Scanning at Scale: Comparison of Whole Slide Imaging Devices in a Clinical Setting (2025) Quality Management System in Clinical Digital Pathology Operations at a Tertiary Cancer Center (2023) Interobserver Variability Across Whole-Slide Imaging Systems (2026) Deployment of AI-Driven Automated Quality Control of Whole-Slide Images in a Large Tertiary Cancer Center (2026)

In this episode, Nick Best is joined by Dr. Orly Ardon, Director of Digital Pathology Operations at Memorial Sloan Kettering Cancer Center, and Chet Kondragunta, CEO of Aira Matrix, at ECP 2026 in Stockholm to explore the growing importance of image quality and automated quality control in digital pathology. Drawing on four published research papers, Orly shares insights from Memorial Sloan Kettering's experience of scanning over 11 million slides, discussing the challenges of maintaining consistent image quality as laboratories scale. Together, they explore the limitations of manual quality control, differences between whole-slide imaging systems, and how AI-driven automation can help standardise image assessment, reduce technician workloads and support more reliable clinical workflows. Research papers discussed in this episode: Digital Slide Scanning at Scale: Comparison of Whole Slide Imaging Devices in a Clinical Setting (2025) Quality Management System in Clinical Digital Pathology Operations at a Tertiary Cancer Center (2023) Interobserver Variability Across Whole-Slide Imaging Systems (2026) Deployment of AI-Driven Automated Quality Control of Whole-Slide Images in a Large Tertiary Cancer Center (2026) Stay tuned for Part 2, where the discussion turns to the practical implementation of automated QC and its impact on laboratory operations.

Following the recent collaboration between Source BioScience and Indica Labs, join us for this short Pathology News interview, where Sidney Ocanagil-Tunstall speaks with Klaudyna Johnstone, Commercial Director at Source BioScience, and Fatlum Hasaj, Clinical Application Specialist at Indica Labs, about supporting NHS histopathology services through flexible outsourcing and digital workflows.In the conversation, Klaudyna explains how Source BioScience helps laboratories manage fluctuating workloads and meet turnaround targets. Fatlum introduces HALO AP, discussing how the platform brings together whole-slide images, case information, reporting and collaboration tools, and how the teams worked together to integrate it into Source BioScience’s existing systems.Looking ahead, the interview explores how workflow automation, AI integration and greater connectivity could help laboratories scale their services while maintaining quality and supporting patient care.

In this episode, Sidney Ocanagil-Tunstall is joined by Professor Nasir Rajpoot, Director of the Tissue Image Analytics (TIA) Centre at the University of Warwick, to explore a career that has developed alongside the evolution of digital and computational pathology. Nasir reflects on his journey from computer science and early image analysis to becoming one of the pioneers working with pathology images, sharing the challenges of building a field before whole slide imaging, large datasets and modern AI tools became widely available. He also discusses the early research and collaborations that helped build the computational pathology community and the landmark digital pathology validation work at University Hospitals Coventry and Warwickshire, which helped accelerate adoption across the UK.

In the second part of this conversation, Sidney Ocanagil-Tunstall continues his discussion with Professor Nasir Rajpoot, Director of the Tissue Image Analytics (TIA) Centre at the University of Warwick, exploring the milestones and collaborations that helped move digital and computational pathology forward.Nasir reflects on establishing Warwick’s Bioimage Analysis Lab in 2011/12, as a decade of persistence began to translate into growing momentum and new partnerships. He discusses how collaborations with researchers in the life sciences, including those working with fluorescence images, helped shape this early period and bring together a community around bioimage analysis.

Following the recent collaboration between Techcyte and Mayo Clinic, join us for this short Pathology News interview, where Sidney Ocanagil-Tunstall speaks with Ben Cahoon, CEO of Techcyte, about the development of Fusion AP and what the platform could mean for the future of digital pathology. In the conversation, Ben explains how Fusion AP brings together anatomic and clinical pathology workflows, connecting information from the LIS and EHR while deeply integrating third-party AI tools into a single platform. He also discusses how the collaboration with Mayo Clinic helped shape a flexible system that can be configured around the different needs and workflows of individual laboratories. Looking ahead, the interview explores Techcyte’s vision for a more connected and consolidated pathology ecosystem, bringing histology, cytology, AI and other pathology workflows together. Ben also discusses the wider rollout of Fusion AP, its recent CE-IVDR mark, and plans to expand the platform across pathology organisations worldwide.

In this episode, Sidney Ocanagil-Tunstall is joined by Professor Nasir Rajpoot, Director of the Tissue Image Analytics (TIA) Centre at the University of Warwick, to explore a career that has developed alongside the evolution of digital and computational pathology.Nasir reflects on his journey from computer science and early image analysis to becoming one of the pioneers working with pathology images, sharing the challenges of building a field before whole slide imaging, large datasets and modern AI tools became widely available. He also discusses the early research and collaborations that helped build the computational pathology community and the landmark digital pathology validation work at University Hospitals Coventry and Warwickshire, which helped accelerate adoption across the UK.

Join Pathology News for this short interview, where Sidney Ocanagil-Tunstall speaks with Professor David Brettle, Chief Scientific Officer at Leeds Teaching Hospitals NHS Trust, and Steven Lynum, President and CEO of Epredia, about Tango - a new technology designed to tackle stain variability and support greater consistency across histopathology laboratories. In the conversation, David and Steven explore the story behind Tango, its development through a collaboration between Leeds and Epredia, and how improving upstream staining consistency could help create higher-quality, more standardised data for digital pathology and AI. Looking ahead, the discussion considers Tango’s potential to support AI readiness by reducing variability, making algorithms easier to develop and deploy, and helping move AI towards more scalable use in routine pathology workflows.

wing the recent partnership between Leica Biosystems and DiaDeep, join us for this short Pathology News interview, where Sidney Ocanagil-Tunstall speaks with Bryce Brown, Director of Product Enablement at Leica Biosystems, about what the collaboration means for AI adoption in digital pathology. In the conversation, Bryce explores how DiaDeep’s biomarker quantification tools are being integrated into the Aperio AI Store, helping laboratories access specialised AI applications through a single digital pathology workflow. He also discusses the Store’s flexible approach to licensing and its growing ecosystem of AI partners. Looking ahead, the discussion considers how Leica Biosystems is working to move AI beyond proof-of-concept and into practical, routine pathology workflows, with a focus on accessibility, integration and supporting pathologists as AI adoption continues to grow.

In this episode, Sidney Ocanagil-Tunstall is joined by Dr Adam Shephard, Assistant Professor at the University of Warwick's Tissue Image Analytics (TIA) Centre, and Dr Hanya Mahmood, Senior Clinical Lecturer and Honorary Consultant Oral Surgeon at the University of Sheffield, to explore how artificial intelligence is transforming the diagnosis and management of oral epithelial dysplasia (OED). The conversation focuses on OYDN, an AI-powered computational pathology model developed through a collaboration between the TIA Centre and the University of Sheffield. Adam and Hanya discuss how the technology supports more objective diagnosis, improves risk stratification for patients at risk of developing oral cancer, and is helping uncover novel digital biomarkers that could shape future treatment strategies. The discussion broadens into the challenges of translating AI from research into routine clinical practice, exploring the importance of explainable AI, robust validation, clinician confidence, and NHS adoption. Looking ahead, the guests share their vision for how AI can support pathologists, standardise clinical decision-making, and ultimately improve outcomes for patients through earlier, more accurate intervention.

In this episode, Sidney Ocanagil-Tunstall continues the conversation with Dr Julia Jones, Elsa Santos and Cara Brodie from the Cancer Research UK Cambridge Institute, focusing on the technologies underpinning modern digital pathology workflows. The discussion explores how the team evaluates and procures whole slide scanners, balancing image quality, flexibility and downstream compatibility over speed alone. They also examine the growing importance of colour standardisation across scanning platforms, the challenges it presents for image analysis, and how AI could help overcome variability to deliver more robust and reproducible results. Looking ahead, the conversation turns to the future of multimodal imaging, data integration and artificial intelligence, alongside practical advice for researchers adopting new technologies in digital pathology and spatial biology.

In this episode, Sidney Ocanagil-Tunstall visits the Cancer Research UK Cambridge Institute to explore how digital pathology and spatial biology are transforming cancer research. Joined by Dr Julia Jones, Scientific Manager for In Situ Hybridisation, alongside Senior Scientific Associates Elsa Santos and Cara Brodie, the conversation examines the Institute’s long-standing commitment to innovation, from early adoption of digital pathology workflows to the integration of advanced spatial omics technologies. The discussion covers image analysis, multiplex assays, multimodal approaches combining RNA and protein detection, and the growing role of spatial biology in understanding the tumour microenvironment. The team also reflects on the practical challenges of implementation, including costs, technology selection, collaboration, and the importance of shared expertise in driving the next generation of cancer research.

In this episode, Sidney Ocanagil-Tunstall continues the conversation with Dr Asif Naseem, GP and specialist in preventative healthcare and men's health, and Dr Beat Rheiner, CEO of Proteomedix, this time turning to what a better diagnostic pathway could actually look like in practice. Building on the challenges of PSA testing explored in Episode 1, the discussion moves into the role of emerging tools like Proclarix in supporting smarter clinical decision-making. Asif shares his real-world experience using Proclarix as a private GP, including how it has helped him identify patients who may benefit from further investigation, and those who can safely avoid unnecessary downstream procedures. The conversation broadens into a wider discussion around diagnostics implementation and adoption,  exploring the relationship between laboratory and clinician as part of the same clinical decision-making process, and why awareness of such diagnostic tools remains one of the most important barriers to overcome. As Asif puts it: new tools need to be more accessible, more widely understood, and correctly used. Proclarix is a blood-based test which works in the PSA "grey zone" of 2-10ng/ML to better stratify risk of clinically significant prostate cancer.